Cargando…
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection
With over 3.5 billion people at risk and approximately 390 million human infections per year, dengue virus (DENV) disease strains health care resources worldwide. Previously, we and others established models for DENV pathogenesis in mice that completely lack subunits of the receptors (Ifnar and Ifng...
Autores principales: | Pinto, Amelia K., Brien, James D., Lam, Chia-Ying Kao, Johnson, Syd, Chiang, Cindy, Hiscott, John, Sarathy, Vanessa V., Barrett, Alan D., Shresta, Sujan, Diamond, Michael S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Microbiology
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600115/ https://www.ncbi.nlm.nih.gov/pubmed/26374123 http://dx.doi.org/10.1128/mBio.01316-15 |
Ejemplares similares
-
Role of Complement in Dengue Virus Infection: Protection or Pathogenesis?
por: Shresta, Sujan
Publicado: (2012) -
Mouse Models to Study Dengue Virus Immunology and Pathogenesis
por: Zellweger, Raphaël M., et al.
Publicado: (2014) -
Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development
por: Elong Ngono, Annie, et al.
Publicado: (2019) -
Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent Zika virus challenge
por: Wen, Jinsheng, et al.
Publicado: (2017) -
STAT2 Mediates Innate Immunity to Dengue Virus in the Absence of STAT1 via the Type I Interferon Receptor
por: Perry, Stuart T., et al.
Publicado: (2011)